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A B S T R A C T
In the period between the December 2000 and September 2004, altogether 13 patients underwent preoperative por-
tal vein embolization (PPVE); 9 patients with colorectal metastases and 4 patients with hepatocellular carcinoma. The
indirect splenic portography was performed after catheter was introduced into superior mesenteric artery via femoral
artery approach. The portal vein was punctured percutaneously transhepatic under fluoroscopy. Following portogra-
phy, selected portal vein segments were embolized by injecting polyvinil alcohol (PVA) particles until stasis of blood
flow was achieved. Proximal parts of branches and the channel in the liver parenchyma were occluded with Gelfoam
particles. The increase of the remnant liver parenchyma was measured by magnetic resonance imaging. Two patients
experienced post-embolization syndrome and another one had subcapsular hematoma. The volume of the liver paren-
chyma increased minimally for 8% and maximally for 109%. Altogether, 10 patients underwent surgical resection. In
two patients, the disease progressed and carcinoma spread to the previously healthy liver lobe and in one there was no
hypertrophy and we decided for artery chemoembolization (AC). The results show that PPVE triggers a strong regener-
ative response resulting in hypertrophy of normal liver parenchyma and expand possibilities of curative surgery for pa-
tients who would not otherwise have been candidates for extended resection.
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Introduction
Hepatic malignant tumors are characterized by ag-
gressive growth and can cause local complications. The-
refore, curative surgical resection is considered the me-
thod of choice in the treatment of primary hepatic
tumors and metastases.
The incidence of hepatocellular carcinoma (HCC)
shows marked geographical variation, with the majority
of cases arising in high-risk areas such as Africa and
Asia. In Europe, HCC is relatively rare. Between 60 to
80% of patients with HCC have underlying cirrhosis1.
The majority of patients treated with preoperative por-
tal vein embolization (PPVE) had liver metastases from
colorectal carcinoma. Long-term results after liver re-
section show 5-year survival rates up to 70%. Five-year
disease-free rate is up to 40%2. The resection of colo-
rectal and other metastases can also produce favorable
survival results3. With surgical resection up to 60% of
liver parenchyma can be removed4.
One of the most critical elements in the evaluation of
potential surgical candidates is prediction of postopera-
tive liver function. There is no test to determine the
maximum parenchymal volume to be resected and pre-
dict the function of the remnant liver after surgery2.
When the surgical resection involves the removal of a
large part of the affected liver parenchyma, there is a
risk that it may not leave enough liver tissue to sustain
life. Such problems can be mostly anticipated in case of
large tumors, especially if they are located in the central
portion of the liver (segments 4, 5 and 8), or in case of
the small left lateral section and a extended right hepa-
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tectomy is required removing most of the liver paren-
chyma. Similar difficulties can also be expected when
extensive resection is required in patients whose liver
function is compromised by underlying cirrhosis, severe
cholestasis, extensive fibrosis and steatosis5.
The problem of postoperative liver failure following
hepatic resection can be solved by liver transplanta-
tion6, which, when used in patients with small tumors
and metastases, can yield similar or even better 5-year
survival rate than resection7. In patients with the un-
derlying functional liver parenchyma defect such as cir-
rhosis, the best outcome is offered by transplantation.
However, the limited organ supply makes this option
unattainable for some. Therefore another approach is
used to improve the outcome of surgical resection, i.e.
the preoperative increase of liver volume so as to stimu-
late compensatory hypertrophy of non-cancerous liver
parenchyma areas8–11. Liver parenchyma is namely
known to possess remarkable regenerative capacity and
the liver cell proliferation is possible under humoral
control. Regulators are various metabolites, polypep-
tides and hormones. It is known that such agents can be
found in portal blood circulation12.
The goal PPVE is to induce atrophy of liver paren-
chyma affected by tumor and compensatory hypertro-
phy of non-diseased liver parenchyma, increasing the
possibility of resection of primary tumor as well as
metastases5,13–15. Apart from restricting the centripetal
progression of tumor thrombus, PPVE prevents tumor
cell dissemination through the portal circulation, and in
combination with the transcatheter arterial chemoem-
bolization (TACE) causes ischemic necrosis of the tu-
mour16,17. This method has proved very effective with
primary liver tumors and metastases regardless whe-
ther the unresected liver area was normal or affected by
cirrhosis18.
Careful injection of embolic material is therefore
mandatory. Balloon occlusion catheters can also be used
to unwanted reflux of the embolic material to non-target
organs8. PVA particles of various sizes and Gelfoam par-
ticles used in our procedures proved as an appropriate
solution, since they did not migrate to surrounding un-
affected liver parenchyma. From the tumour's perspec-
tive various approaches can be used, i.e. contralateral
as well as ipsilateral. Also, the puncture can be US- or
fluoroscopy-guided. In exceptional cases, the procedure
can also be performed by surgical preparation of mesen-
teric vein and positioning of an appropriate chateter5.
Subjects and Methods
In the period between the years 2000 and 2003, 13
patients with unresectable liver tumors (9 men and 3
women, median age 62.8 years, 8 colorectal hepatic
metastases and 4 hepatocellular carcinoma) were se-
lected for PPVE. Patient selection was based on the con-
sensus of the abdominal surgeon and the radiologist,
and the size of the lesion to be removed. They were all
potentially at risk of postoperative liver failure. In most
cases, patients left anatomical liver lobe (lateral sec-
tion) was too small and predicted future liver remnant
(FLR) volume was less than 25% of the total liver vol-
ume. In 2 patients liver function was further compro-
mised by underlying cirrhosis19. Patients were informed
about the surgical procedure and the risks and compli-
cations associated with the procedure, and their consent
to surgery was obtained.
PPVE was performed on digital substraction angio-
graphy (DSA), Philips – INTEGRIS C – 2000, under
general anesthesia. The anesthesiology technique was
chosen on the basis of the patient’s age, constitution,
clinical status and concomitant illnesses as well as fol-
lowing the radiologist’s requests for the performance of
the procedure. The anesthetic technique that allows for
unconsciousness, lack of movement and rapid recovery
is always preferred.
Just prior to the procedure an intravenous premedi-
cation (Midazolam 1–3mg) was administered to the pa-
tients. The introduction into the anaesthesia25 was per-
formed either with Propofol (1.5–2.5 mg/kg) or Etomi-
date (0.2–0.4 mg/kg) and Fentanyl in the dose 1–3
g/kg. For the muscular relaxation and intubation Atra-
curium 0.3 mg/kg or Mivacurium 0.2 mg/kg was applied.
The procedure was performed under balanced, general
anaesthesia with mixture of O2 and N2O and Sevofluran
(MAC=1.7%) together with periodically administered
boluses of Fentanyl paying regard to the patient's re-
sponse to stimulation during the procedure. During the
procedure the patients were monitored by means of a
standard noninvasive monitoring. Patients were extu-
bated when their protective laryngeal reflexes had been
present. The anesthesia itself did not trigger any com-
plications during the procedures.
For all patients we initially used a retrograde com-
mon femoral artery (CFA) approach. After the CFA was
punctured a 5F sheat was placed and 5F diagnostic
catheter Simon-Sidewinder 2 (Angiopass Plus, Angio-
med – Bard Inc.) was positioned into origin of superior
mesenteric artery (SMA) and indirect splenoportogra-
phy was obtained.
Under fluoroscopy guidance portal vein (PV) was
punctured with 22G needle (IPS, Angiomed – Bard Inc.)
and a 0.35 guide wire was introduced and a 5F sheat
with coiled shaft design (Super-Arrow Flex, Arrow Inc.)
was positioned. The sheat construction offers extraordi-
nary flexibillity and allows at the end of the procedure
occlusion of the liver parenchyma channel with greater
Gelfoam particles.
A 4F Cobra diagnostic catheter was inserted and a
preprocedural portography was obtained to display the
portal vein branches. We usually chose between a softer
catheter with soft tip (Balton Medical Equipment, Po-
land) and a little stronger one with exellent placement
accuracy and good pushability (Angiopass Plus – Bard
Inc.). The catheter tip was selectively placed into seg-
mental branches and the embolization material was ap-
plied under fluoroscopy control until complete stasis
was achieved.
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We started with spheric particles size 100 and con-
cluded with particles up to 1000m (Embosphere – Bio-
sphere Medical Inc.). Proximal vein segments were oc-
cluded with Gelfoam particles and in two patient with
large size coils. (COOK Inc.)
All patients underwent embolization of the right por-
tal vein and its segmental branches.
The procedure lasted on average 23 minutes. After
the procedure, the patients remained in hospital for 48
hours on average. In 10 patients a surgical resection
was performed on average one month after the embo-
lization.
Liver volumetry
The liver parenchymal volume and the volume of un-
affected parenchyma were measured using magnetic-re-
sonance tomography (MRT) – TOSHIBA Visart 1.5 Te-
sla in transverse plane in T1 sequence20. The entire
liver parenchyma was covered with thick 8-mm sections
with 2-mm gap. The intervals were taken into account
in the calculation. The boundaries of the liver and of the
residual non-diseased parenchyma were outlined by a
trackball-driven cursor and the volume was calculated
using the corresponding software. The volume was mea-
sured before PPVE and 30 days after it.
Results
The procedure was successful in all patients and pri-
mary technical success was achieved. All but one pa-
tient tolerated the procedure well. Volume changes were
measured using MRT volumetric measurements of
transversal slices of liver parenchyma before PPVE and
just before the planned operation. The volume of the en-
tire liver and the volume of unaffected remnant liver pa-
renchyma were measured. FLR exhibited 8–109% in-
crease in volume. On average, the liver parenchymal
volume increased by 158 cm3 or 41%.
Liver resection was successfully performed in 10 out
of 13 patients approximately 40 days following PPVE.
In one patient the disease progressed and in two pa-
tients the expected hypertrophy did not occur and for
that reason only AK was performed.
Complications
In one patient bleeding was reason for developing a
subcapsular liver heamatoma. Also post-embolization
syndrome was present, accompanied by severe pain and
symptoms of diaphragm irritation. These changes were
treated conservatively. The controlling MRT examina-
tion showed that the disease progressed and that meta-
stases spread to previously healthy liver parts, thus pre-
venting surgical resection.
In 2 patients mild symptoms of post-embolization
syndrome (increase of temperature to 37.6 °C and slight
right upper quadrant pain) were noted one day after the
procedure.
Discussion
Papers reporting the use of PPVE before hepatic re-
section first appeared in the literature in the 1980’s.
Since then many authors have reported favorable out-
comes for patients with primary hepatic carcinoma that
underwent PPVE8. Beneficial effects of PPVE in pa-
tients with colorectal carcinoma metastases6,10,18 and
those with bile duct carcinoma8,16 have been less fre-
quently reported.
The commonly used embolic materials include etha-
nol, fibrin glue, lipiodol, Gelfoam, gelatine sponge parti-
cles, Polyvinil alcohol particles (PVA), Embosphere par-
ticles and various coils9,14,24. We mostly used the PVA
and Embosphere particles of various sizes and Gelfoam.
No evidence was found in the literature of the superior-
ity of one material over another.
The embolization of the segmental branches of the
portal vein induces ischemia of embolized area, causing
an increased flow of portal blood to non-embolized ar-
eas. This triggers paracrine and endocrine response,
which results in hypertrophy of the remnant part of
liver parenchyma. During liver regeneration, increased
levels of various mediators such as growth factor, trans-
forming growth factor  and hepatocyte growth factor
can be detected, which is why it is believed that liver re-
generation is controlled and managed by all these medi-
ators together16,17.
All the above-mentioned factors also have a promot-
ing effect on the development of tumors. It is well known
that tumor development and accelerated tumor growth
directly coincide with liver regeneration22,23. Elias ob-
served and described the accelerated metastasis growth
in patient who underwent PPVE6.
This is the reason why PPVE remains limited to pa-
tients with no alternative way of treatment available.
One should bear in mind that the above effects can be
produced after every liver resection during parenchyma
regeneration. The accelerated growth can uncover mi-
crometastases and/or occult tumors in segments that
seemed unaffected, thus preventing the planned resec-
tion. Altogether 9 patients underwent surgical resection
about one month after the embolization. In two patients
the disease progressed and the surgical resection was
not possible. In one patient the expected hypertrophy
was not achieved, which indicated a need for further
treatment with TACE.
In two patients TACE had been performed before
PPVE. It is known from the literature that the combina-
tion of PPVE and TACE provokes substantially greater
necrosis of tumor and metastases than TACE alone.
Moreover, PPVE reduces the possibility of intrahepatic
migration of tumor cells and prevents the spread of
metastases8.
Mean FLR increased by almost 40%, allowing sur-
gery in patients initially deemed unresectable and im-
proving their chance of survival in the event of any pos-
sible postoperative complications.
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Conclusion
A rapidly increasing number of patients surgically
treated due to HCC or colorectal metastases in Maribor
General Hospital have brought about the question of pa-
tient's ability to tolerate a liver resection. To address
this problem, PPVE was introduced in an attempt to
turn patient´s unresectable disease to resectable one,
making them candidates for curative liver resection.
The results of our three-year work are comparable to
the data published by other authors and confirm that
PPVE induces a strong regenerative response, which is
reflected in the hypertrophy of the FLR, increasing the
resectability rate. The method was equally successful in
patients with HCC and those with colorectal metasta-
ses. Still, embolization procedures are not without risk.
They require the skill and experience of the interven-
tional radiologist.
An evaluation of all treatment options available to a
patient is of vital importance. In carefully selected pa-
tients with no alternative treatment option available
PPVE may prove beneficial. By inducing the hypertrophy
of the FLR, PPVE can improve patients’ survival chances.
Even though the time interval between the emboli-
zation and the surgical resection is not yet determined,
many authors believe that it plays a very important
role2,4,5,8. It is widely considered that the interval should
be longer in patients with additionally compromised
liver parenchyma. As the time interval between the
embolization and operation appears to be more impor-
tant than the maximum hypertrophy achieved, it is of
paramount importance that it is optimized. The mean
time was 33 days. As the procedure is limited to a subset
of patients, where no alternative treatments seem possi-
ble and where the resection may prove fatal, a careful
patient selection is an important issue. In such cases
PPVE may enable patients to benefit from potentially
curative resection by increasing the remnant liver volu-
me prior to an operation.
Even though the method has been known for more
than 20 years, there is a need for more randomized stud-
ies that would provide the evidence of effectiveness of
PPVE in increasing the safety of surgical resections and
reducing the postoperative liver dysfunction5.
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SELEKTIVNA EMBOLIJA PORTALNE VENE KAO UVOD U OPSE@AN KIRUR[KI ZAHVAT
S A @ E T A K
Izme|u prosinca 2000. godine i rujna 2004. godine, 13 bolesnika podvrgnuto je preoperativnoj embolizaciji vene
vratarice od kojih je 9 imalo metastaze kolorektalnog karcinoma, a 4 pacijenta imalo je hepatocelularni karcinom.
Indirektna flebografija vene lijenalis izvedena je nakon {to je kateter uveden u gornju mezenteri~nu arteriju femo-
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ralnim putem. Vena vratarica punktirana je perkutano pod kontrolom dijaskopije. Nakon flebografije vene vratarice,
pojedini njeni djelovi embolizirani su ubrizgavanjem ~estica polivinil alkohola. Proksimalni dio ogranka vene vra-
tarice i kanal unutar jetrenog parenhima embolizirani su Gelfoam ~esticama. Porast jetrenog parenhima mjeren je
magnetskom rezonancom. Dva bolesnika imala su postembolizacijski sindrom, dok je kod jednog nastao subkapsu-
larni hematom. Volumen jetrenog parenhima porastao je za minimalno 8%, a maksimalno 109%. Deset bolesnika
podvrgnuto je kirur{koj resekciji. U dva bolesnika bolest je napredovala i karcinom se pro{irio na prije zdravi jetreni
re`anj, a kod jednog bolesnika nije do{lo do hipertrofije te smo se odlu~ili za kemoembolizaciju. Rezultati pokazuju da
preoperativna embolizacija vene vratarice poti~e jaki regenerativni odgovor koji se o~ituje hipertrofijom urednog je-
trenog parenhima, te pro{iruje mogu}nosti kirur{kog lije~enja bolesnika koji ina~e nisu kandidati za pro{irenu re-
sekciju.
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